How effective is Keppra for Epilepsy? (a real world drug study)

Summary:

Overall ratings: 3.7/5
Long term ratings: 3.8/5

This is a phase IV clinical study of how effective Keppra (levetiracetam) is for Epilepsy and for what kind of people. The study is created by eHealthMe from 704 Keppra users and is updated continuously.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Epilepsy?

Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures) is found to be associated with 1,164 drugs and 1,776 conditions by eHealthMe. Check the latest studies of Epilepsy.


On Jul, 05, 2026

704 people are studied for taking Keppra in Epilepsy

Overall effectiveness (number of people):

Does Keppra work for your Epilepsy (overall)?

Long term (1+ years) effectiveness (number of people):

Does Keppra work for your Epilepsy (long term)?

Keppra effectiveness for Epilepsy (number of people):

Overall:
  • not at all: 13
  • somewhat: 91
  • moderate: 183
  • high: 248
  • very high: 169
Long Term:
  • not at all: 3
  • somewhat: 48
  • moderate: 123
  • high: 169
  • very high: 135

Gender of people who take Keppra for Epilepsy *:

  • female: 65.2 %
  • male: 34.8 %

Age of people who take Keppra for Epilepsy *:

  • 0-1: 0.71 %
  • 2-9: 5.11 %
  • 10-19: 12.36 %
  • 20-29: 21.59 %
  • 30-39: 20.45 %
  • 40-49: 14.2 %
  • 50-59: 14.35 %
  • 60+: 11.22 %

Who find Keppra more effective for Epilepsy?

Gender of people who take Keppra for Epilepsy *:

  • female: 64.75 %
  • male: 35.25 %

Age of people who take Keppra for Epilepsy *:

  • 0-1: 0.72 %
  • 2-9: 4.08 %
  • 10-19: 10.31 %
  • 20-29: 22.06 %
  • 30-39: 20.62 %
  • 40-49: 14.15 %
  • 50-59: 13.91 %
  • 60+: 14.15 %

* Approximation only. Some reports may have incomplete information.

Do you take Keppra?

- You can start a phase IV clinical trial to monitor Keppra safety and effectiveness.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Alternative drugs to, pros and cons of:

Treatments, associated drugs and conditions:

How the study uses the data?

The study is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: